



IN VITRO ASSAYS & SERVICE CATALOG

TABLE OF CONTENTS

WHO WE ARE		4
ASSAY CATALOG		5
INFLAMMATION	5_	
AGING	6	
POLLUTANT TOXICITY	6	
ANTI-MICROBIAL	7	
ANTIOXIDANT	8	
SKIN BRIGHTENING	8	
SKIN TANNING	8	
WOUND HEALING	9	
METABOLISM	9	
SAFETY AND REGULATORY SUPPORT		10
FORMULATION		11
CUSTOMIZED SCREENING		12
OTHER SERVICES		12



WHO WE ARE

Signum Biosciences is a private biotech company founded in 2003 from technologies developed by Dr. Jeffry Stock at Princeton University. With over 18 years of developing multiple ingredients and botanical extracts from discovery to fully formulated skin-care products that are on the market, Signum possesses the ability to streamline your research and product development. We specialize in producing customized claim support and dermatological efficacy testing to provide clients with robust scientific data needed to substantiate product claims and/or compare head-to-head versus competitors. We work with clients ranging from multi-national companies to virtual biotech startups, all projects are welcomed. We have highly trained scientists who can tailor a research plan to fit your requirements be it efficacy, safety, regulatory or scientific marketing. Whether you are in early discovery phase, development, clinical stage, or ready to commercialize your products, Signum can provide the following services to aid you on your product development path.

- Standard assays to determine activity profile
- Safety and regulatory support
- Customized screening
- Topical formulation development, stability, and dermal penetration studies
- Filling and packing finished products for consumer use (<2500 units)
- Scientific marketing and peer-reviewed publishing of results
- Botanical extraction, characterization, and manufacturing
- Compound synthesis and manufacturing

Signum is the solution to optimize your R&D screening, product development and customized research at a reduced cost compared to larger CRO's and CMO's. We provide superior service to differentiate your product, so contact us today. Our discussions will provide the scientific excellence and quality your product deserves.

For more information contact:
Eduardo Perez, PhD
Chief Scientific Officer
11 Deer Park Drive
Monmouth Junction, NJ 08852
eperez@signumbio.com
Office: 732-329-6344 ext. 214

ASSAY CATALOG

Signum has a host of standard assays that can be performed to test your ingredient, compound, or formulated product. Below is a representative list of some of the assays we conduct regularly. We possess *in vitro* capabilities for molecular techniques including enzymatic evaluation, gene and protein expression, cell line expansion, intracellular pathway analysis using colorimetric, fluorescent, or histology-based methods.

INFLAMMATION

CATALOG #	MODEL	STIMULUS/INDUCER	ENDPOINT	METHOD	REFERENCE
SKI-001		TPA/PMA	Chemical irritation	Cytokine	Glucocorticoid
SKI-002				ĒLISA	
SKI-003	Human Epidermal Keratinocytes			Sunburn Cells	
SKI-004	(NHEKs) or Human Reconstructed Epidermis (EpiDerm™)	Epidermis (EpiDerm™) UVB Photodamage	Photodamage	DNA pyrimidine dimers	Vitamin C
SKI-005				Lipid Peroxides	
SKI-006	Peripheral Blood Mononuclear Cells (PBMC)	anti-CD3/CD28	T-cell activation	Th2/Th17- marker ELISA	TGF-beta
SKI-007		ATP-gS	ATP inflammation		
SKI-008	Human Dermal Microvascular Endothelial Cells (HDMECs)	anti-microbial peptide (LL-37)	Cathelicidin		Glucocorticoid
SKI-009		Nickel sulfate	Nickel Allergy	MTS Viability, Cytokine ELISA	
SKI-010	Human Epidermal Keratinocytes (NHEKs)	C. acnes	IL-8, IL-1b		Dexamethasone
SKI-011	Human Reconstructed Cornea (EpiOcular™)	Dry Eye	Viability, MMP9		Dexametrasone
SKI-012	Human Epidermal Keratinocytes (NHEKs)	TPA/PMA or UVB	COX-2	ELISA	Indomethacin
SKI-013	Human COX-2 Enzyme	Arachidonic Acid Substrate	COX-2 inhibition	Biochemical	or Diclofenac

AGING

CATALOG #	MODEL	STIMULUS/INDUCER	ENDPOINT	METHOD	REFERENCE
SKA-001	Human Epidermal Keratinocytes (NHEKs)	Cell Confluence	Epidermal Differentiation	Keratin-1, Filaggrin, Loricrin	Adapalene
SKA-002		Blue Light	Photoaging	Viability, HAS2	Vitamin C
SKA-003	Human Adult Dermal Fibroblasts	Human Adult Dermal Fibroblasts (HDFs) or Human Reconstructed Epidermis (EpiDermFT™)	Extra cellular matrix expression	MMPs, Collagen, Elastin,	Vitamin C,
				'	Fibronectin,
SKA-004	Lpideimis (LpiDeimi 1)	UVA	Photoaging	Laminin	
SKA-004		H ₂ O ₂	Senescence	Histology	
SKA-006	Human Epidermal Keratinocytes (NHEKs) or Human Reconstructed Epidermis	Basal or UVB	Global Gene Expression	Gene Array	Ascorbic Acid or Retinoic Acid
SKA-007	Human Epidermal Keratinocytes (HaCATs)	Nutrient Starvation	LC3-II	ELISA	Blumilight

POLLUTANT TOXICITY

CATALOG #	MODEL	STIMULUS/INDUCER	ENDPOINT	METHOD	REFERENCE	
TOX-001	Human Epidermal Keratinocytes (NHEKs)	Urban Dust Particulate	Air Pollution		MTS Viability, Cvtokine ELISA Dexameth	
TOX-002	Human Dermal Microvascular	Cadmium	Metal Pollution	MTS Viability, Cytokine ELISA		Dexamethasone
TOX-003	Endothelial Cells (HDMECs)	Nickel	Metal Foliution			

ANTI-MICROBIAL

CATALOG #	MODEL	STIMULUS/INDUCER	ENDPOINT	METHOD	REFERENCE
AMIC-001	Cutibacterium acnes				
AMIC-002	Staphylococcus epidermidis			Culture	
AMIC-003	Staphylococcus aureus	Minimum	Anti-bacterial	Turbidity,	Doxycycline
AMIC-004	Streptococcus pyogenes	inhibitory Concentration	Anti-bacteriai	Colony	
AMIC-005	Escherichia coli		counting	Counting	
AMIC-006	Pseudomonas aeruginosa				Gentamycin
AMIC-007	Candida albicans			Colony counting	Fluconazole
AMIC-008	Aspergillus brasiliensis	TYMC	Anti-fungal		Benzalkonium Chloride
AMC-009	M. luteus				
AMC-010	S. hominis				
AMC-011	S. warneri	Minimum	Growth	Culture	
AMC-012	S. capitis	Inhibitory Concentration	Inhibition	Turbidity	Doxycycline
AMC-013	S. simulans			. a. a. a. a	
AMC-014	C. xerosis				
AMC-015	C. granulosum				

ANTIOXIDANT

CATALOG #	MODEL	STIMULUS/INDUCER	ENDPOINT	METHOD	REFERENCE
AOX-001	Cell-free antioxidant		ROS scavenging	ABTS	
AOX-002	Human Adult Dermal Fibroblasts (HDFs)	H ₂ O ₂	Intracellular ROS	DCF-DA	_
AOX-003	Low Density Lipoproteins	Fe ₂ SO ₄	Lipid Peroxidation	Hydroperoxide	Vitamin C, Ferulic Acid
AOX-004	Microsomes	NADPH/ADP/Fe ³⁺	Membrane MDA	TBARS	
AOX-005	Human Neutrophils HL-60	fMLP/PMA	Cell Oxidative Burst	Colorimetric	Vitamin E

SKIN WHITENING

CATALOG #	MODEL	STIMULUS/INDUCER	ENDPOINT	METHOD	REFERENCE
SKW-001	Cell-free Tyrosinase		Tyrosinase inhibition		
SKW-002	Human Reconstructed Epidermis (MelanoDerm™)	Basal	Melanin content	Colorimetric	Kojic Acid
SKW-003	Epidermal Melanocytes				

SKIN TANNING

CATALOG #	MODEL	STIMULUS/INDUCER	ENDPOINT	METHOD	REFERENCE
SKT-001	Human Reconstructed Epidermis (MelanoDerm™)	Basal	Melanin content	Colorimetric	IBMX
SKT-002	Epidermal Melanocytes				

WOUND HEALING

CATALOG #	MODEL	STIMULUS/INDUCER	ENDPOINT	METHOD	REFERENCE
WH-001	Human Epidermal Keratinocytes (NHEKs)	in vitro wound	Cell Migration	on Histology	EGF
WH-002	Human Dermal Fibroblasts (HDFs)	(scratch assay)			FGF

METABOLISM

CATALOG #	MODEL	STIMULUS/INDUCER	ENDPOINT	METHOD	REFERENCE
MET-001	Human Epidermal Keratinocytes (NHEKs) or Human Reconstructed Epidermis (EpiDerm™)	Basal	Mitochondrial localization	Histology	EGF

SAFETY AND REGULATORY SUPPORT

Equally important to determining if your ingredient possesses beneficial skin properties is to ensure that it is safe when topically applied. We perform a battery of tests to ensure your ingredient possesses a safety profile adherent to industry standards and can provide regulatory support in getting your novel ingredient or extract registered with the Personal Care and Products Council for INCI designation.

CATALOG #	MODEL	STIMULUS/INDUCER	ENDPOINT	METHOD	REFERENCE		
SAF-001	OECD TG 439: Human Reconstructed Epidermis (EpiDerm™)	Basal	Skin Irritation	MTT	SDS		
SAF-002	OECD TG 492: Human Reconstructed Cornea (EpiOcular™)	Basal	Ocular irritation	MTT	Methyl Acetate		
SAF-003	OECD TG 432: Mouse BALB/3T3	1.17.4	Dhatataviaity	Neutral	Chlamananin		
3AF-003	Fibroblasts	UVA Phototoxicity F			Phototoxicity	Red Uptake	Chlorpromazine
SAF-004		UVA			Chlorpromazine		
SAF-005	Human Reconstructed Skin (EpiDerm FT™)	UVB	Photodamage	MTT	Sun Screen		
SAF-006	, , , , , , , , , , , , , , , , , , , ,	Infrared-A			Vitamin C		
SAF-007	OECD TG 428: Skin Absortion	Basal	Dermal Penetration	Franz Cell	Vehicle		

FORMULATION

A big hurdle for developing and launching new skin care products is that most CMOs require 5,000-10,000-unit MOQs, leaving those looking to enter the cosmetic space with large quantities of inventory and increased upfront costs. At Signum, we specialize in working with companies that want to start with lower MOQs to help reduce the initial financial commitment and allow for flexibility with product updates and changes.

Signum has the capabilities to develop your ingredients into any desired formulation (i.e., cream, lotion, gel, toner, serum, sheet mask) or develop a finished turn-key formulation ready for market. Along with formulation development, we perform the following tests to support the commercial launch of your product:

- Stability testing
- Compatibility testing
- Preservative Efficacy Testing (PET)
- Dermal penetration testing
- Microbiological testing
- Safety testing

At Signum we don't have MOQs. Whether you want samples of a product to share with potential investors and or prospective business partners for feedback or 1,000 to 3,000 units for your initial launch, we will work with you to start you on your path to commercial success.



CUSTOMIZED SCREENING

Standard dermatological tests, while effective in many respects, do not always provide the best path forward in characterizing the activity of your ingredient or product. Given our past experience in working to develop and commercialize cosmetics, botanical extracts, pharmaceuticals and nutraceuticals, we possess the innovative capabilities in protocol design, assay development and claim support testing to customize your research plan. With the support of our knowledgeable project management team, we can demonstrate the activity of your molecule or product by personalizing an experimental plan and assay system to produce exciting scientific data to deliver your study objectives and support your product's brand goals.

OTHER SERVICES

Signum strives to offer comprehensive services to our clients and their ingredients or products no matter what stage of development they are in. We have experience taking ingredients from discovery to market and can assist you with all steps along the way. Listed below are some of the additional services that we offer.


- Botanical Extraction
 - Signum has experience fractionating botanical extracts to identify the key ingredients driving activity and characterization. Once identified the extract can be scaled up, assessed for stability, studied analytically to set specifications, and then moved into testing with several formulation prototypes
- Scientific Marketing (manuscripts, posters, etc.)
 - o Signum understands the importance of giving your product credibility and differentiation from competitors. We offer scientific writing services such as manuscripts or posters for your ingredient or product which can be submitted to present in scientific conferences or for peer-reviewed publication.
- Medicinal Chemistry and Scale Manufacturing
 - o Given our expertise in Rx development and synthesizing novel compounds, we can assist your efforts in synthesizing compounds, making a series of derivatives, or scaling up your current ingredient to kilo scale. Beyond that, our Florida facility can perform large scale manufacturing to 100+ kg once your product is on the market

Early development and precise strategy can reduce costs and accelerate timelines. Contact us to learn more about all our services and how Signum Biosciences can bring maximum benefit to your development program and product.

For more information contact:
Eduardo Perez, PhD
Chief Scientific Officer
11 Deer Park Drive
Monmouth Junction, NJ 08852
eperez@signumbio.com
Office: 732-329-6344 ext. 214









THANK YOU